Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Investigates Ties Of India’s Lupin, Others To Generics Antitrust Acts

This article was originally published in PharmAsia News

Executive Summary

The European Union says it is investigating India's Lupin and other international drug makers for possible involvement in collusion involving generic blood-pressure drugs. According to the European Commission, the executive branch of the EU, it suspects Lupin, Teva Pharmaceutical, Krka, Mylan and Unichem Laboratories subsidiaries of participating in an effort to keep a generic off the market. The antitrust investigation is part of a wider commission probe into the operations of the pharmaceutical industry in general, including how makers of branded drugs compete with generics makers. The company at the core of this probe is Les Laboratoires Servier, maker of the Coversyl, or Aceon (perindopril) ACE Inhibitor. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072415

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel